This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
European Haemophilia Consortium. Haemophilia care in Europe: 2009-2018. Available from https://www.ehc.eu/haemophilia-care-in-europe/ (accessed December 2023).European Haemophilia Consortium.Haemophilia care in Europe: 2009-2018. Available from https://www.ehc.eu/haemophilia-care-in-europe/(accessed December 2023).Search in Google Scholar
World Federation of Haemophilia. Report on the Annual Global Survey 2021. WFH, 2022. Available from https://www1.wfh.org/publications/files/pdf-2399.pdf (accessed December 2023).World Federation of Haemophilia.Report on the Annual Global Survey 2021.WFH,2022. Available from https://www1.wfh.org/publications/files/pdf-2399.pdf(accessed December 2023).Search in Google Scholar
Rayment R, Chalmers E, Forsyth K, et al.; British Society for Haematology. Guidelines on the use of prophylactic factor replacement for children and adults with Haemophilia A and B. Br J Haematol 2020; 190(5): 684-695. doi: 10.1111/bjh.16704.RaymentRChalmersEForsythK.;British Society for Haematology. Guidelines on the use of prophylactic factor replacement for children and adults with Haemophilia A and B.Br J Haematol2020;190(5):684-695. doi:10.1111/bjh.16704.Open DOISearch in Google Scholar
Chowdary P. Nonfactor therapies: new approaches to prophylactic treatment of haemophilia. Hamostaseologie 2021; 41(4): 247-256. doi: 10.105/a-1424-7900.ChowdaryP.Nonfactor therapies: new approaches to prophylactic treatment of haemophilia.Hamostaseologie2021;41(4):247-256. doi:10.105/a-1424-7900.Open DOISearch in Google Scholar
European Medicines Agency. First gene therapy to treat severe haemophilia A. Available from https://www.ema.europa.eu/en/news/first-gene-therapy-treat-severe-haemophilia (accessed December 2023).European Medicines Agency.First gene therapy to treat severe haemophilia A. Available from https://www.ema.europa.eu/en/news/first-gene-therapy-treat-severe-haemophilia(accessed December 2023).Search in Google Scholar
European Medicines Agency. First gene therapy to treat severe haemophilia B. Available from https://www.ema.europa.eu/en/news/first-gene-therapy-treat-haemophilia-b (accessed December 2023).European Medicines Agency.First gene therapy to treat severe haemophilia B. Available from https://www.ema.europa.eu/en/news/first-gene-therapy-treat-haemophilia-b(accessed December 2023).Search in Google Scholar
van Galen K, Lavin M, Skouw-Rasmussen N, et al.; European Haemophilia Consortium (EHC) and the European Association for Haemophilia and Allied Disorders (EAHAD). European Principles of Care for Women and Girls with Inherited Bleeding Disorders. Haemophilia 2021; 27(5): 837-847. doi: 10.1111/hae.14379.van GalenKLavinMSkouw-RasmussenNEuropean Haemophilia Consortium (EHC) and the European Association for Haemophilia and Allied Disorders (EAHAD).European Principles of Care for Women and Girls with Inherited Bleeding Disorders.Haemophilia2021;27(5):837-847. doi:10.1111/hae.14379.Open DOISearch in Google Scholar
Lewandowska M, Nasr S, Shapiro A. Therapeutic and technological advancements in haemophilia care: Quantum leaps forward. Haemophilia 2022; 28 Suppl 4: 77-92. doi: 10.1111/hae.14531.LewandowskaMNasrSShapiroA.Therapeutic and technological advancements in haemophilia care: Quantum leaps forward.Haemophilia2022;28Suppl 4:77-92. doi:10.1111/hae.14531.Open DOISearch in Google Scholar
Inherited and Acquired Haemophilia and other Bleeding Disorders Peer Review Programme. Overview Report. May 2020. Available from https://haemophilia.org.uk/wp-content/uploads/pdf/IABD-Overview-Report-2020-V1-20200514.pdf (accessed September 2023).Inherited and Acquired Haemophilia and other Bleeding Disorders Peer Review Programme. Overview Report.May2020. Available from https://haemophilia.org.uk/wp-content/uploads/pdf/IABD-Overview-Report-2020-V1-20200514.pdf(accessed September 2023).Search in Google Scholar
Hughes T, Brok-Kristensen M, Gargeya Y, et al. “What more can we ask for?”: an ethnographic study of challenges and possibilities for people living with haemophilia. J Haem Pract 2020; 7(1): 25-36. doi: 10.17225/jhp00151.HughesTBrok-KristensenMGargeyaY.“What more can we ask for?”: an ethnographic study of challenges and possibilities for people living with haemophilia.J Haem Pract2020;7(1):25-36. doi:10.17225/jhp00151.Open DOISearch in Google Scholar
Hughes T, Brok-Kristensen M, Gargeya Y, et al. Treating for stability: an ethnographic study of aspirations and limitations in haemophilia treatment in Europe. J Haem Pract 2020; 7(1): 165-172. doi: 10.17225/jhp00169.HughesTBrok-KristensenMGargeyaY.Treating for stability: an ethnographic study of aspirations and limitations in haemophilia treatment in Europe.J Haem Pract2020;7(1):165-172. doi:10.17225/jhp00169.Open DOISearch in Google Scholar
Recht M, Konkle BA, Jackson E, et al. Recognising the need for personalisation of haemophilia patient-reported outcomes in the prophylaxis era. Haemophilia 2016; 22(6): 825-832. doi: 10.1111/hae.13066.RechtMKonkleBAJacksonE.Recognising the need for personalisation of haemophilia patient-reported outcomes in the prophylaxis era.Haemophilia2016;22(6):825-832. doi:10.1111/hae.13066.Open DOISearch in Google Scholar
National Institute for Health and Care Research. Underserved communities. Available from https://www.nihr.ac.uk/about-us/our-key-priorities/under-served-communities.htm (accessed September 2023).National Institute for Health and Care Research.Underserved communities. Available from https://www.nihr.ac.uk/about-us/our-key-priorities/under-served-communities.htm(accessed September 2023).Search in Google Scholar
Skinner MW, Dolan G, Eichler H, O’Mahony B; International Haemophilia Strategy Council. A preliminary application of a haemophilia value framework to emerging therapies in haemophilia. Haemophilia 2022; 28 Suppl 2: 9-18. doi: 10.1111/hae.14511.SkinnerMWDolanGEichlerHO’MahonyBInternational Haemophilia Strategy Council.A preliminary application of a haemophilia value framework to emerging therapies in haemophilia.Haemophilia2022;28Suppl 2:9-18. doi:10.1111/hae.14511.Open DOISearch in Google Scholar
Hermans C, Noone D, Benson D, et al. Hemophilia treatment in 2021: Choosing the “optimal” treatment using an integrative, patient-oriented approach to shared decision-making between patients and clinicians. Blood Rev 2022; 52: 100890. doi: 10.1016/j.blre.2021.100890.HermansCNooneDBensonD.Hemophilia treatment in 2021: Choosing the “optimal” treatment using an integrative, patient-oriented approach to shared decision-making between patients and clinicians.Blood Rev2022;52:100890. doi:10.1016/j.blre.2021.100890.Open DOISearch in Google Scholar
Hermans C, Kulkarni R. Women with bleeding disorders. Haemophilia 2018; 24 Suppl 6: 29-36. doi: 10.1111/hae.13502.HermansCKulkarniR.Women with bleeding disorders.Haemophilia2018;24Suppl 6:29-36. doi:10.1111/hae.13502.Open DOISearch in Google Scholar
UKHCDO and NHD. UKHCDO Annual Report 2022 & Bleeding Disorder Statistics for the Financial Year 2021/2022. UKHCDO, 2022. Available from https://www.ukhcdo.org/wp-content/uploads/2022/12/UKHCDO-Annual-Report-2022-2021-22-Data.pdf (accessed September 2023).UKHCDO and NHD.UKHCDO Annual Report 2022 & Bleeding Disorder Statistics for the Financial Year 2021/2022.UKHCDO,2022. Available from https://www.ukhcdo.org/wp-content/uploads/2022/12/UKHCDO-Annual-Report-2022-2021-22-Data.pdf(accessed September 2023).Search in Google Scholar
Oxford Haemophilia Centre. Internal data provided by speaker.Oxford Haemophilia Centre.Internal data provided by speaker.Search in Google Scholar
Parker M, Hannah M, Zia A. “If I wasn’t a girl”: Experiences of adolescent girls with heavy menstrual bleeding and inherited bleeding disorders. Res Pract Thromb Haemost 2022; 6(4): e12727. doi: 10.1002/rth2.12727.ParkerMHannahMZiaA.“If I wasn’t a girl”: Experiences of adolescent girls with heavy menstrual bleeding and inherited bleeding disorders.Res Pract Thromb Haemost2022;6(4): e12727. doi:10.1002/rth2.12727.Open DOISearch in Google Scholar
Khair K, Pollard D, Steadman L, Jenner K, Chaplin S. The views of women with bleeding disorders: Results from the Cinderella study. Haemophilia 2022; 28(2): 316-325. doi: 10.1111/hae.14514.KhairKPollardDSteadmanLJennerKChaplinS.The views of women with bleeding disorders: Results from the Cinderella study.Haemophilia2022;28(2):316-325. doi:10.1111/hae.14514.Open DOISearch in Google Scholar
Chaigneau M, Botros M, Grabell J, Hopman W, James P. Challenges and knowledge gaps facing hemophilia carriers today: Perspectives from patients and health care providers. Res Pract Thromb Haemost 2022; 6(6): e12783. doi: 10.1002/rth2.12783.ChaigneauMBotrosMGrabellJHopmanWJamesP.Challenges and knowledge gaps facing hemophilia carriers today: Perspectives from patients and health care providers.Res Pract Thromb Haemost2022;6(6): e12783. doi:10.1002/rth2.12783.Open DOISearch in Google Scholar
Noone D, Skouw-Rasmussen N, Lavin M, van Galen K, Kadir RA. Barriers and challenges faced by women with congenital bleeding disorders in Europe: Results of a patient survey conducted by the European Haemophilia Consortium. Haemophilia 2019; 25(3): 468-474. doi: 10.1111/13722.NooneDSkouw-RasmussenNLavinMvan GalenKKadirRA.Barriers and challenges faced by women with congenital bleeding disorders in Europe: Results of a patient survey conducted by the European Haemophilia Consortium.Haemophilia2019;25(3):468-474. doi:10.1111/13722.Open DOISearch in Google Scholar
Whitaker S, Aiston H, Hung WT, Pink R, Mangles S. Haemophilia Carriers Experience Study (CARES): A mixed method exploration into the experience of women who are carriers of haemophilia. Haemophilia 2021; 27(5): 848-853. doi: 10.1111/hae.14360.WhitakerSAistonHHungWTPinkRManglesS.Haemophilia Carriers Experience Study (CARES): A mixed method exploration into the experience of women who are carriers of haemophilia.Haemophilia2021;27(5):848-853. doi:10.1111/hae.14360.Open DOISearch in Google Scholar
van Galen KPM, d’Oiron R, James P, et al. A new hemophilia carrier nomenclature to define hemophilia in women and girls: Communication from the SSC of the ISTH. J Thromb Haemost 2021; 19(8): 1883-1887. doi: 10.1111/jth.15397.van GalenKPMd’OironRJamesP.A new hemophilia carrier nomenclature to define hemophilia in women and girls: Communication from the SSC of the ISTH.J Thromb Haemost2021;19(8):1883-1887. doi:10.1111/jth.15397.Open DOISearch in Google Scholar
Scott MJ, Xiang H, Hart DP, et al. Treatment regimens and outcomes in severe and moderate haemophilia A in the UK: The THUNDER study. Haemophilia 2019; 25(2): 205-212. doi: 10.1111/hae.13616.ScottMJXiangHHartDP.Treatment regimens and outcomes in severe and moderate haemophilia A in the UK: The THUNDER study.Haemophilia2019;25(2):205-212. doi:10.1111/hae.13616.Open DOISearch in Google Scholar
Pulles AE, Mastbergen SC, Schutgens REG, Lafeber FPJG, van Vulpen LFD. Pathophysiology of hemophilic arthropathy and potential targets for therapy. Pharmacol Res 2017; 115: 192-199. doi: 10.1016/j,phrs.2016.11.032.PullesAEMastbergenSCSchutgensREGLafeberFPJGvan VulpenLFD.Pathophysiology of hemophilic arthropathy and potential targets for therapy.Pharmacol Res2017;115:192-199. doi:10.1016/j,phrs.2016.11.032.Open DOISearch in Google Scholar
Puetz J. Nano-evidence for joint microbleeds in hemophlia patients. J Thromb Haemost 2018; 16(10): 1914-1917. doi: 10.1111/jth.14242.PuetzJ.Nano-evidence for joint microbleeds in hemophlia patients.J Thromb Haemost2018;16(10):1914-1917. doi:10.1111/jth.14242.Open DOISearch in Google Scholar
Baud-huin M, Duplomb L, Téletchéa S, et al. Factor VIII-von Willebrand factor complex inhibits osteoclastogenesis and controls cell survival. J Biol Chem 2009; 284(46): 31704-13. doi: 10.1074/jbc.M109.030312.Baud-huinMDuplombLTéletchéaS.Factor VIII-von Willebrand factor complex inhibits osteoclastogenesis and controls cell survival.J Biol Chem2009;284(46):31704-13. doi:10.1074/jbc.M109.030312.Open DOISearch in Google Scholar
Mackie EJ, Loh L-H, Sivagurunathan S, et al. Protease-activated receptors in the musculoskeletal system. Int J Biochem Cell Biol 2008; 40(6-7): 1169-84. doi: 10.1016/j.biocel.2007.12.003.MackieEJLohL-HSivagurunathanS.Protease-activated receptors in the musculoskeletal system.Int J Biochem Cell Biol2008;40(6-7):1169-84. doi:10.1016/j.biocel.2007.12.003.Open DOISearch in Google Scholar
Gerstner G, Damiano ML, Tom A, et al. Prevalence and risk factors associated with decreased bone mineral density in patients with haemophilia. Haemophilia 2009; 15(2): 559-65. doi: 10.1111/j.1365-2516.2008.01963.x.GerstnerGDamianoMLTomA.Prevalence and risk factors associated with decreased bone mineral density in patients with haemophilia.Haemophilia2009;15(2):559-65. doi:10.1111/j.1365-2516.2008.01963.x.Open DOISearch in Google Scholar
Tuan S-H, Hu L-Y, Sun S-F, et al. Risk of osteoporotic fractures as a consequence of haemophilia: A nationwide populationbased cohort study. Haemophilia 2019; 25(5): 876-884. doi: 10.1111/hae.13814.TuanS-HHuL-YSunS-F.Risk of osteoporotic fractures as a consequence of haemophilia: A nationwide populationbased cohort study.Haemophilia2019;25(5):876-884. doi:10.1111/hae.13814.Open DOISearch in Google Scholar
Gregory WJ, Saygin D. Assessment of physical activity and muscle function in adult inflammatory myopathies. Curr Rheumatol Rep 2022; 24(3): 54-63. doi: 10.1007/s11926-022-01059-5.GregoryWJSayginD.Assessment of physical activity and muscle function in adult inflammatory myopathies.Curr Rheumatol Rep2022;24(3):54-63. doi:10.1007/s11926-022-01059-5.Open DOISearch in Google Scholar
Ilias I, Milionis C, Zoumakis E. An overview of glucocorticoid-induced osteoporosis. [updated 2022 Mar 19]. In: Feingold KR, Anawalt B, Blackman MR, et al. (eds.). Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-. Available from https://www.ncbi.nlm.nih.gov/books/NBK278968/ (accessed September 2023).IliasIMilionisCZoumakisE.An overview of glucocorticoid-induced osteoporosis. [updated 2022 Mar 19]. In:FeingoldKRAnawaltBBlackmanMR. (eds.).Endotext[Internet].South Dartmouth (MA):MDText.com, Inc.;2000-.Available from https://www.ncbi.nlm.nih.gov/books/NBK278968/(accessed September 2023).Search in Google Scholar
Chambers H, Gregory W, McCrum C, et al. Rheumatology Physiotherapy Capabilities Framework: Screening, assessment and specialist management. 2021. Available from https://www.rheumatology.org.uk/Portals/0/Documents/Policy/Rheumatology-physiotherapy-capabilities-framework.pdf?ver=2021-09-24-100925-060 (accessed November 2023).ChambersHGregoryWMcCrumC.Rheumatology Physiotherapy Capabilities Framework: Screening, assessment and specialist management.2021. Available from https://www.rheumatology.org.uk/Portals/0/Documents/Policy/Rheumatology-physiotherapy-capabilities-framework.pdf?ver=2021-09-24-100925-060(accessed November 2023).Search in Google Scholar
Brooke-Wavell K, Skelton DA, Barker KL, et al. Strong, steady and straight: UK consensus statement on physical activity and exercise for osteoporosis. Br J Sports Med 2022; 56(15): 837-846. doi: 10.1136/bjsports-2021-104634.Brooke-WavellKSkeltonDABarkerKL.Strong, steady and straight: UK consensus statement on physical activity and exercise for osteoporosis.Br J Sports Med2022;56(15):837-846. doi:10.1136/bjsports-2021-104634.Open DOISearch in Google Scholar
Featherston R, Downie LE, Vogel AP, Galvin KL. Decision making biases in the allied health care professions: A systematic scoping review. PLoS One 2020; 15(10): e0240716. doi: 10.1371/journal.pone.0240716.FeatherstonRDownieLEVogelAPGalvinKL.Decision making biases in the allied health care professions: A systematic scoping review.PLoS One2020;15(10): e0240716. doi:10.1371/journal.pone.0240716.Open DOISearch in Google Scholar
Coulter A, Collins A. Making shared decision-making a reality: No decision about me, without me. London: The King’s Fund; 2011. Available from https://www.kingsfund.org.uk/publications/making-shared-decision-making-reality (accessed September 2023).CoulterACollinsA.Making shared decision-making a reality: No decision about me, without me.London:The King’s Fund;2011. Available from https://www.kingsfund.org.uk/publications/making-shared-decision-making-reality(accessed September 2023).Search in Google Scholar
Elwyn G, Durand MA, Song J, et al. A three-talk model for shared decision making: multistage consultation process. BMJ 2017; 359: j4891. doi: 10.1136/bmj.j4891.ElwynGDurandMASongJ.A three-talk model for shared decision making: multistage consultation process.BMJ2017;359: j4891. doi:10.1136/bmj.j4891.Open DOISearch in Google Scholar
World Federation of Hemophilia. WFH shared decision making tool for hemophilia treatment. 2023. Available from https://elearning.wfh.org/resource/wfh-shared-decision-making-tool-for-hemophilia-treatment/#information (accessed September 2023).World Federation of Hemophilia.WFH shared decision making tool for hemophilia treatment.2023. Available from https://elearning.wfh.org/resource/wfh-shared-decision-making-tool-for-hemophilia-treatment/#information(accessed September 2023).Search in Google Scholar